ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
REGULATORY INTELLIGENCERecallNotable

Johnson, S C and Son Initiates Class II Recall of babyganics Zinc Oxide Sunscreen Due to Stability Failures

RM
Rohan MehtaView Profile →
Senior Supply Chain Intelligence Analyst
EXECUTIVE SUMMARY

Johnson, S C and Son, Inc. has initiated a Class II recall of 57,184 bottles of babyganics Sheer Blend SPF 50 Mineral Sunscreen (zinc oxide 20%) due to failed stability specifications, specifically physical ingredient separation. This event underscores critical quality control and supply chain oversight challenges for procurement and regulatory teams, particularly for products manufactured internationally, demanding immediate review of supplier qualification and stability testing protocols.

What the FDA Found: Summary of Recall Findings and Product Specifications

Johnson, S C and Son, Inc., headquartered in Racine, WI, has initiated a voluntary Class II recall, identified as D-0298-2025, for a significant quantity of its babyganics Sheer Blend, SPF 50 Mineral Sunscreen Fragrance Free. This recall, formally initiated on January 8, 2025, and subsequently classified by the FDA on March 25, 2025, encompasses 57,184 bottles distributed nationwide across the USA. The core issue driving this action stems from critical quality concerns uncovered during routine stability monitoring: the product, which relies on 20% zinc oxide as its primary active ingredient, exhibited observable physical separation of ingredients. This failure to meet established stability specifications directly compromises the product's integrity and its ability to deliver consistent sun protection, posing a tangible risk to consumers. The affected product units include two distinct sizes: 1.7 FL OZ (50 mL) bottles, identifiable by UPC 810035921658 and Lot #: 097C4/C080316 with an expiration date of March 31, 2026; and 8 FL OZ (236 mL) bottles, marked with UPC 810035921382 and Lot #: 177K3/A303407, expiring on October 31, 2025. For procurement directors and regulatory affairs heads, this Class II classification signifies that the product's use or exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This level of recall demands immediate attention and robust corrective actions. The detail that the product is "Made in Canada" but distributed by KAS Direct, LLC from Racine, WI, underscores a critical aspect of global supply chain management. It places the onus on Johnson, S C and Son, Inc. to ensure that their international contract manufacturing partners adhere to stringent quality standards and stability protocols. This incident serves as a stark reminder that lapses in product quality, even if voluntarily addressed, can lead to significant brand reputational damage for babyganics and substantial commercial disruption, necessitating a thorough review of all outsourced manufacturing agreements.

Critical Implications for Product Stability and Quality Assurance

The observed physical separation of ingredients in the babyganics SPF 50 Mineral Sunscreen highlights a fundamental challenge in formulating and manufacturing stable topical products, particularly those containing high concentrations of active pharmaceutical ingredients (APIs) like 20% zinc oxide. Zinc oxide functions as a physical sunscreen, creating a barrier on the skin to reflect UV radiation. Its efficacy is directly dependent on its uniform dispersion throughout the product matrix. When physical separation occurs, as identified during stability monitoring for lots 097C4/C080316 and 177K3/A303407, the active ingredient can settle or aggregate, leading to an inconsistent concentration profile within the bottle. This non-uniformity means that consumers applying the product may receive inadequate sun protection in certain areas, thereby failing to achieve the stated SPF 50 efficacy and potentially increasing their risk of sun damage. For business development executives and supply chain VPs, this stability failure mandates an immediate and comprehensive re-evaluation of current quality assurance frameworks, particularly concerning the design and execution of stability testing protocols for finished goods. While the issue was caught during "routine stability monitoring," the fact that it progressed to a recall indicates a need for more predictive or robust testing methods, or a re-assessment of the formulation's inherent stability. Companies involved in sourcing or developing similar zinc oxide-based formulations must scrutinize their own stability programs, ensuring that both accelerated and long-term studies are sufficiently rigorous to detect and predict such physical instabilities well before market release. The commercial ramifications of a Class II recall, impacting 57,184 bottles distributed nationwide, extend far beyond the direct costs of retrieval and destruction, encompassing significant reputational damage for the babyganics brand and potential erosion of consumer trust in its product reliability and safety within the highly competitive mineral sunscreen market segment.

Supply Chain Vulnerabilities and International Manufacturing Oversight

The supply chain structure for the recalled babyganics SPF 50 Mineral Sunscreen, involving manufacturing in Canada and distribution by KAS Direct, LLC from Racine, WI, underscores significant vulnerabilities inherent in globally dispersed production networks. For procurement directors, this cross-border arrangement necessitates an exceptionally stringent approach to the selection, qualification, and ongoing oversight of contract manufacturing organizations (CMOs). Johnson, S C and Son, Inc., as the recalling firm and brand owner, retains ultimate responsibility for the quality, safety, and regulatory compliance of products bearing its name, irrespective of the manufacturing location. This incident strongly suggests a potential deficiency in the oversight mechanisms applied to the Canadian manufacturing partner's quality management systems, particularly concerning formulation stability and process control during production. Supply chain VPs must recognize that outsourcing manufacturing, especially to international partners, demands comprehensive quality agreements. These agreements must meticulously detail stability testing protocols, robust change control procedures, and explicit audit rights, including the ability to conduct unannounced inspections. The nationwide recall of 57,184 bottles across the USA illustrates the extensive commercial exposure that can arise from a single quality lapse at the manufacturing source. To mitigate such risks, companies must implement rigorous incoming material and finished product testing regimes, complemented by regular, thorough audits of their CMOs. Furthermore, a deep understanding of the regulatory requirements and expectations in both the country of manufacture (Canada) and the country of distribution (United States) is paramount for regulatory affairs heads. This recall serves as a critical reminder that a proactive quality culture and vigilant oversight are indispensable for safeguarding product integrity and preventing costly, brand-damaging market withdrawals in increasingly complex global supply chains.

Proactive Risk Mitigation and Future Compliance Strategies

In light of the babyganics SPF 50 Mineral Sunscreen recall, senior decision-makers across procurement, regulatory affairs, and business development must immediately implement robust and proactive risk mitigation strategies. Firstly, procurement teams should initiate an urgent and comprehensive review of all existing contracts with their Contract Manufacturing Organizations (CMOs), particularly those involved in producing complex formulations or over-the-counter (OTC) drug products like sunscreens. This review must ensure that stability testing requirements are not only explicitly defined but also rigorously audited and fully compliant with FDA expectations. This includes a thorough verification of the CMOs' quality management systems, their capabilities for conducting thorough root cause analyses, and their implementation of effective Corrective and Preventive Actions (CAPA). Regulatory affairs heads are advised to critically assess their internal processes for monitoring and evaluating product stability data. Any identified deviations or out-of-specification results must trigger immediate, comprehensive investigations, with clear communication protocols established with manufacturing partners for prompt reporting of all quality excursions. For business development executives, comprehending the profound impact of product recalls on market entry strategies and brand equity is paramount. This event underscores the critical need for robust contingency planning, which includes proactively identifying and qualifying alternative suppliers or developing formulations that inherently demonstrate superior stability profiles. While the ChemLifeIntel knowledge graph does not currently provide specific alternative suppliers for zinc oxide sunscreen, companies should actively engage with established API manufacturers and contract formulators renowned for their robust quality systems and expertise in the dermatological and OTC sectors. This strategic diversification of the supply base is essential for enhancing resilience against similar quality-related disruptions and protecting long-term market position.

ChemLifeIntel analysis · Rohan Mehta. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 1,200+ pharmaceutical and chemical companies across the global value chain.

Covering 1,200+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
3d ago

CDSCO Enacts Sweeping Regulatory Changes Across India's Pharma and Medical Device Sectors

India's CDSCO has issued numerous critical regulatory updates, impacting drug formulations, medical devices, and animal health. These changes, including product restrictions, revised fees, and new import rules, necessitate immediate review by procurement, regulatory affairs, and supply chain leaders to maintain compliance and mitigate operational risks across the Indian market.

REGULATORY INTELLIGENCE
3d ago

ANSM Fines Novo Nordisk and Eli Lilly for GLP-1 Obesity Campaign Breaches, Novo Nordisk Explores Legal Challenge

France's ANSM has fined Novo Nordisk and Eli Lilly for obesity campaign breaches related to GLP-1 analogue misuse. This action underscores escalating regulatory scrutiny on high-demand drug marketing. Novo Nordisk is considering a legal challenge, signaling potential prolonged legal and reputational impacts for major pharmaceutical players in the European market.

REGULATORY INTELLIGENCE
4d ago

FDA Faces Pressure to Restrict Livestock Antibiotic Use: Major Commercial Implications for Chemical and Life Sciences

Over 60 organizations have petitioned the FDA to revoke approvals for antibiotic use in livestock for disease prevention and growth promotion. This action, driven by concerns over antibiotic resistance and its human health toll, signals potential significant regulatory shifts. Procurement, supply chain, and regulatory affairs leaders must prepare for market disruption and new compliance requirements.

REGULATORY INTELLIGENCE
4d ago

Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition

Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.

REGULATORY INTELLIGENCE
4d ago

Health Canada's Drug Product Database: A Critical Resource for Market Intelligence and Regulatory Compliance

Health Canada's Drug Product Database (DPD), last updated March 1, 2019, offers vital intelligence for market access and regulatory compliance. This comprehensive online tool allows stakeholders to query drug identification numbers (DINs), ATC codes, and company data. For procurement, regulatory, and business development executives, the DPD is indispensable for strategic planning and risk management within the Canadian pharmaceutical landscape.

REGULATORY INTELLIGENCE
4d ago

CDSCO Authorizes Oseltamivir Outlets: Clarifying India's Supply Channels for H1N1 Antivirals

India's CDSCO has published a list of authorized outlets for oseltamivir formulation, critical for H1N1 swine flu. This action clarifies legitimate supply channels for this Schedule X drug, signaling intensified regulatory oversight in India's pharmaceutical sector. Procurement and supply chain leaders must ensure compliance with these defined distribution networks to mitigate risks and maintain market access.

REGULATORY INTELLIGENCE
5d ago

Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat

Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.

REGULATORY INTELLIGENCE
6d ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6d ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

REGULATORY INTELLIGENCE
6d ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
6d ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
6d ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

ENTITY HUBS

Entities in this Brief

Johnson & Johnson
company hub
Open company hub